(0.53%) 5 073.25 points
(0.41%) 38 224 points
(0.64%) 17 550 points
(0.71%) $79.56
(1.71%) $1.965
(0.65%) $2 326.00
(0.31%) $26.83
(1.58%) $970.00
(-0.04%) $0.933
(-0.06%) $11.02
(-0.06%) $0.798
(-0.73%) $92.58
Live Chart Being Loaded With Signals
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China...
Stats | |
---|---|
本日の出来高 | 60 000.00 |
平均出来高 | 5.03M |
時価総額 | 522.67M |
EPS | HKD0 ( 2023-08-28 ) |
次の収益日 | ( HKD0 ) 2024-05-16 |
Last Dividend | HKD0.00224 ( 2007-08-22 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 8.60 |
ATR14 | HKD0.00100 (1.12%) |
Uni-Bio Science Group 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Uni-Bio Science Group 財務諸表
Annual | 2023 |
収益: | HKD484.72M |
総利益: | HKD390.46M (80.55 %) |
EPS: | HKD0.0111 |
FY | 2023 |
収益: | HKD484.72M |
総利益: | HKD390.46M (80.55 %) |
EPS: | HKD0.0111 |
FY | 2022 |
収益: | HKD440.32M |
総利益: | HKD334.88M (76.06 %) |
EPS: | HKD0.00600 |
FY | 2021 |
収益: | HKD353.41M |
総利益: | HKD277.01M (78.38 %) |
EPS: | HKD-0.00306 |
Financial Reports:
No articles found.
Uni-Bio Science Group Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.00224 | 2007-08-22 |
Last Dividend | HKD0.00224 | 2007-08-22 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | HKD0.00224 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.39 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.43 | |
Div. Directional Score | 7.92 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2317.HK | Ex Dividend Junior | 2023-09-14 | Annually | 0 | 0.00% | |
1285.HK | Ex Dividend Junior | 2023-07-18 | Annually | 0 | 0.00% | |
0345.HK | Ex Dividend Knight | 2023-08-31 | Annually | 0 | 0.00% | |
6098.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1846.HK | Ex Dividend Knight | 2023-09-11 | Annually | 0 | 0.00% | |
0869.HK | Ex Dividend Knight | 2023-09-07 | Annually | 0 | 0.00% | |
0016.HK | Ex Dividend Knight | 2023-11-06 | Semi-Annually | 0 | 0.00% | |
2638.HK | Ex Dividend Junior | 2023-08-15 | Semi-Annually | 0 | 0.00% | |
1417.HK | No Dividend Player | 2023-06-19 | Annually | 0 | 0.00% | |
0506.HK | Ex Dividend Knight | 2023-06-13 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.146 | 1.500 | 7.08 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.259 | 1.200 | 1.356 | 1.628 | [0 - 0.3] |
returnOnEquityTTM | 0.441 | 1.500 | 6.21 | 9.31 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.07 | 0.800 | 4.63 | 3.70 | [1 - 3] |
quickRatioTTM | 1.870 | 0.800 | 3.71 | 2.96 | [0.8 - 2.5] |
cashRatioTTM | 1.126 | 1.500 | 4.86 | 7.28 | [0.2 - 2] |
debtRatioTTM | 0.112 | -1.500 | 8.14 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 139.39 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0180 | 2.00 | 9.99 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0180 | 2.00 | 9.99 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.178 | -1.500 | 9.29 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.807 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.150 | 1.000 | 9.00 | 9.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.50 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 1.773 | 0.800 | 1.511 | 1.209 | [0.5 - 2] |
Total Score | 11.41 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.97 | 1.000 | 9.60 | 0 | [1 - 100] |
returnOnEquityTTM | 0.441 | 2.50 | 7.56 | 9.31 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0180 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0180 | 2.00 | 9.99 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.114 | 1.500 | -2.58 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.158 | 1.000 | 8.56 | 0 | [0.1 - 0.5] |
Total Score | 4.43 |
Uni-Bio Science Group
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。